Oxford Biomedica (LSE: OXB) is a leading, fully integrated, cell and gene therapy group.
We have built a sector leading viral vector platform, including our lentiviral vector delivery system, LentiVector® platform, which we leverage to develop in vivo and ex vivo products both in-house and with partners. We have also created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, CNS disorders and liver diseases.
Building on our world leading position in lentiviral vectors and success in the adenovirus vector-based AstraZeneca COVID-19 vaccine, we have demonstrated the versatility of our platform and have extended our scope to all types of viral vectors.
Oxford Biomedica has a number of further partnerships, including with Novartis, Juno Therapeutics/ Bristol Myers Squibb, Boehringer Ingelheim, Beam Therapeutics, Arcellx, Cabaletta, Orchard Therapeutics and Santen.
Additionally, we have a three-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine.
Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In early 2022, Oxford Biomedica announced that it was broadening its leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business, Oxford Biomedica Solutions, based near Boston, Massachusetts, with Homology Medicines as a 20% owner.
We have built a sector leading viral vector platform, including our lentiviral vector delivery system, LentiVector® platform, which we leverage to develop in vivo and ex vivo products both in-house and with partners. We have also created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, CNS disorders and liver diseases.
Building on our world leading position in lentiviral vectors and success in the adenovirus vector-based AstraZeneca COVID-19 vaccine, we have demonstrated the versatility of our platform and have extended our scope to all types of viral vectors.
Oxford Biomedica has a number of further partnerships, including with Novartis, Juno Therapeutics/ Bristol Myers Squibb, Boehringer Ingelheim, Beam Therapeutics, Arcellx, Cabaletta, Orchard Therapeutics and Santen.
Additionally, we have a three-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine.
Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In early 2022, Oxford Biomedica announced that it was broadening its leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business, Oxford Biomedica Solutions, based near Boston, Massachusetts, with Homology Medicines as a 20% owner.
Location: United Kingdom
Employees: 1-10
Total raised: $80.94M
Founded date: 1995
Investors 1
| Date | Name | Website |
| - | Oxford Uni... | innovation... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.01.2026 | - | $80.94M | - |
Mentions in press and media 13
| Date | Title | Description |
| 15.01.2026 | Oxford Biomedica share prices jumps after takeover talks | Oxford Biomedica’s share price has rocketed in early morning trading after Swedish private equity firm EQT entered takeover talks for the gene and cell therapy group. Shares jumped 10.65 per cent to 889 pence, with shares rocketing 121.4 pe... |
| 25.10.2024 | The Future of Bioprocessing: ArcticZymes Takes Center Stage at ESGCT 2024 | In the heart of Rome, a revolution is brewing. The European Society of Gene and Cell Therapy (ESGCT) 2024 conference has become a beacon for innovation. Among the shining stars is ArcticZymes Technologies ASA, a Norwegian company that is re... |
| 24.10.2024 | ArcticZymes Highlights Industry-Leading Success at ESGCT 2024 | ArcticZymes Highlights Industry-Leading Success at ESGCT 2024 Thu, Oct 24, 2024 08:04 CET Report this content Rome, Italy – October 24, 2024 – ArcticZymes Technologies ASA (OSE: AZT), a global leader in enzyme innovation for bioprocessing, ... |
| 25.06.2024 | ArcticZymes Technologies Announces Nomination of Dr. Frank Mathias as Chairman of the Board | ArcticZymes Technologies Announces Nomination of Dr. Frank Mathias as Chairman of the Board Tue, Jun 25, 2024 08:26 CET Report this content Tromsø, Norway – June 25, 2024 – ArcticZymes Technologies (OSE:AZT) is pleased to announce the nomin... |
| 17.09.2020 | OXFORD BIOMEDICA PLC Oxford Biomedica : interim results for thesix months ended 30 June 2020 | Oxford, UK - 17 September 2020: Oxford Biomedica plc ('Oxford Biomedica' or 'the Group') (LSE: OXB), a leading gene and cell therapy group, today announces interim results for the six months ended 30 June 2020. FINANCIAL HIGHLIGHTS • Revenu... |
| 17.09.2020 | OXFORD BIOMEDICA PLC Oxford Biomedica : OXB Interim Results FY20 RNS FINAL.pdf | Page 1 of 29 OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2020 Oxford, UK - 17 September 2020: Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy... |
| 26.06.2019 | Oxford Biomedica, Santen ink gene therapy pact; DayTwo raises $31M in Series B round | → British gene and cell therapy company Oxford Biomedica {LSE: $OXB} is joining forces with Japan’s Santen Pharmaceutical to develop gene therapies for inherited retinal diseases. Oxford is entitled to an undisclos... |
| 30.05.2019 | Novo's investment arm injects $67.5M in Oxford Biomedica; Abacus Medicine delays IPO plans | → The investment arm of Danish drugmaker Novo Nordisk $NVO is investing £53.5 million (about $67.5 million) in UK-based gene and cell therapy group Oxford Biomedica (LSE:OXB), in exchange for 10.1% of the company’s outsta... |
| 13.03.2019 | Microsoft, Oxford Biomedica to apply cloud, machine learning to improving gene therapy | Most gene therapies in development today rely on viral vectors, whereby a specially engineered virus is used to transfect cells that carry defective genes and insert the corrected genes into them. The only gene therapy with Food and Drug Ad... |
| 06.07.2017 | Novartis turns to Oxford BioMedica for a major CAR-T supply deal | Oxford BioMedica has scored a major supply contract with Novartis for the lentiviral vectors the pharma giant uses in its CAR-T drugs, including the industry-leading CTL019, now under FDA review. Oxford BioMedica is g... |
Show more